Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.

Wood CL, O'Dorisio MS, Vassalo LM, Malarkey WB, O'Dorisio TM

Regulatory peptides1 Nov 1985Cited by 23 (Europe PMC)

PMID3001842DOI10.1016/0167-0115(85)90065-5PepBankPUB-03001842

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In GH3 rat pituitary tumor cells, VIP bound a single class of high affinity sites with a KD of 17 nM, a higher affinity than PHI (275 nM) or GHRF (1380 nM).
In plain wordsIn rat pituitary tumour cells in culture, VIP bound its receptor more tightly than PHI or GHRF did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP binding affinity (KD) on GH3 cells
Study
ratn: not reported in source
GH3 rat pituitary tumor cell line
Comparator
PHI and human pancreatic GHRF
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Measurements
KD
17 nM
VIP, GH3 cells
Source sentences
Summary
Studies using 125I-VIP and unlabeled competing peptides revealed a single class of high affinity binding sites with a dissociation constant (KD) of 17 +/- 2 nM (mean +/- S.E.M.) for VIP, 275 +/- 46 nM for peptide histidine isoleucine (PHI), and 1380 +/- 800 nM for human pancreatic growth hormone rel…
1 context sentence(design, population, supporting numbers)
Summary · context
The vasoactive intestinal polypeptide (VIP) receptor was characterized on the GH3 rat pituitary tumor cell line using competitive binding studies with peptides having sequence homology with VIP.
Report a problemFND-0300184201
02LabIn vitro (cells)Activity measurement
In GH3 rat pituitary tumor cells, VIP stimulated intracellular cAMP accumulation in a dose-dependent manner.
In plain wordsIn rat pituitary tumour cells in culture, VIP raised cAMP levels as the dose went up.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasecAMP accumulation after VIP
Study
ratn: not reported in source
GH3 rat pituitary tumor cell line
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
VIP and PHI each stimulated intracellular cAMP accumulation in a dose-dependent manner
1 context sentence(design, population, supporting numbers)
Summary · context
The vasoactive intestinal polypeptide (VIP) receptor was characterized on the GH3 rat pituitary tumor cell line using competitive binding studies with peptides having sequence homology with VIP.
Report a problemFND-0300184202
03LabIn vitro (cells)Mechanism
In GH3 rat pituitary tumor cells, cross-linking of 125I-VIP was consistent with a 47,000 Mr VIP-binding subunit of, or associated with, the VIP receptor.
In plain wordsIn rat pituitary tumour cells in culture, VIP attached to a protein of about 47,000 size that is part of or linked to its receptor.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableMolecular size of the VIP-binding subunit
Study
ratn: not reported in source
GH3 rat pituitary tumor cell line
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Covalent crosslinking of 125I-VIP to its binding site using either disuccinimidyl suberate (DSS) or ethylene glycol bis(succinimidyl succinate) (EGS) was followed by SDS-PAGE and autoradiography. The result is consistent with an Mr 47 000 VIP-binding subunit comprising or being associated with the V…
1 context sentence(design, population, supporting numbers)
Summary · context
The vasoactive intestinal polypeptide (VIP) receptor was characterized on the GH3 rat pituitary tumor cell line using competitive binding studies with peptides having sequence homology with VIP.
Report a problemFND-0300184205

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In GH3 rat pituitary tumor cells, VIP together with forskolin showed synergism on cAMP accumulation.
In plain wordsIn rat pituitary tumour cells in culture, VIP and forskolin together raised cAMP more than expected from each alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIP synergism with forskolin on cAMP
Study
ratn: not reported in source
GH3 rat pituitary tumor cell line
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
both peptides demonstrated synergism with forskolin.
1 context sentence(design, population, supporting numbers)
Summary · context
The vasoactive intestinal polypeptide (VIP) receptor was characterized on the GH3 rat pituitary tumor cell line using competitive binding studies with peptides having sequence homology with VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0300184203
05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In GH3 rat pituitary tumor cells, VIP plus PHI (1 microM each) caused no significant increase in cAMP over either peptide alone.
In plain wordsIn rat pituitary tumour cells in culture, VIP and PHI together raised cAMP no more than either one alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changecAMP with VIP plus PHI versus either alone
Study
ratn: not reported in source
GH3 rat pituitary tumor cell line
Comparator
VIP alone or PHI alone
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
VIP plus PHI (1 microM each) caused no significant increase in cAMP over either VIP or PHI alone, implying that the two peptides act through the same receptor.
1 context sentence(design, population, supporting numbers)
Summary · context
The vasoactive intestinal polypeptide (VIP) receptor was characterized on the GH3 rat pituitary tumor cell line using competitive binding studies with peptides having sequence homology with VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0300184204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.